Urinary Catheters MarketSize, Share & Industry Analysis, 2026-2034By ProductBy Coating TypeBy MaterialBy ApplicationBy GenderBy End UseBy Distribution Channel
Full title & scope — all 7 axes with their segments
Urinary Catheters Market Size, Share & Industry Analysis, By Product (Indwelling (Foley) Catheters, Intermittent Catheters, External Catheters, Suprapubic Catheter), By Coating Type (Coated Catheters, Uncoated Catheters), By Material (Silicone, Latex, Silicone-Coated Latex, PVC, Other Materials), By Application (Urinary Incontinence, Benign Prostate Hyperplasia, Spinal Cord Injury, Post-Surgical Urinary Retention, Neurogenic Bladder, Chronic Urinary Retention, Prostate Cancer, Other Urological Conditions), By Gender (Male, Female), By End Use (Hospitals, Ambulatory Surgical Centers, Clinics, Long-term Care Facilities/Nursing Homes, Home Care Settings), By Distribution Channel (Direct Tenders, Distributors/Wholesalers, Retail Pharmacies, Online Channels), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.
- 01By ProductIndwelling · Intermittent Catheters · External Catheters
- 02By Coating TypeCoated Catheters · Uncoated Catheters
- 03By MaterialSilicone · Latex · Silicone-Coated Latex
- 04By ApplicationUrinary Incontinence · Benign Prostate Hyperplasia · Spinal Cord Injury
- 05By GenderMale · Female
- 06By End UseHospitals · Ambulatory Surgical Centers · Clinics
- 07By Distribution ChannelDirect Tenders · Distributors/Wholesalers · Retail Pharmacies
- 08By Region
Market Analysis & Outlook
Urinary catheters are medical devices used to drain urine from the bladder when a patient cannot void naturally, ranging from single-use intermittent tubes to catheters left in place for extended periods with an external drainage bag. They are used across indwelling (Foley), intermittent, external (condom-style) and suprapubic forms, each suited to different clinical situations from short-term post-surgical drainage to long-term management of neurogenic or obstructive bladder conditions. Buyers include hospitals, ambulatory surgical centers, long-term care facilities and individual patients managing chronic conditions at home, typically under a clinician's prescription or care plan.
USD 6.3 billion of revenue was recorded in the global urinary catheters market in 2025. By 2034 the figure reaches USD 10.55 billion, a compound annual growth rate of 5.88% through the forecast period, along a series that runs USD 4.55 billion in 2020, USD 6.05 billion in 2024, USD 6.68 billion in 2026 and USD 8.45 billion in 2030.
42% of 2025 revenue sits in Indwelling (Foley) Catheters, worth USD 2.646 billion and rising to USD 3.798 billion at 36% by 2034, the largest product line in both years. Growth is fastest in Intermittent Catheters at 8.08% and slowest in Indwelling (Foley) Catheters at 4.07%. The lines gaining share are Intermittent Catheters. Indwelling (Foley) Catheters, External Catheters and Suprapubic Catheter lose share without losing revenue.
The coating type split puts Coated Catheters first, at USD 3.654 billion and 58% of revenue in 2025, rising to USD 6.858 billion and 65% in 2034. It is also the fastest-growing line on this axis at 7.25%, so the split concentrates rather than balances over the period. It cuts the same total as the product axis from a different commercial angle, so revenue does not add across the two.
The regional order runs from North America at 37% of 2025 revenue down to Middle East and Africa at 6%. North America is worth USD 2.331 billion in 2025 and USD 3.587 billion in 2034; Europe, second at 26%, moves from USD 1.638 billion to USD 2.532 billion. Asia Pacific gain share across the period, so growth is not distributed evenly between regions.
Behind these figures sit five regions, four product lines and seven segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies rather than an independently sourced count, and the same applies to the segment, regional and country breakdowns drawn from it.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global urinary catheters market moves from USD 4.55 billion in 2020 to USD 6.3 billion in 2025 and USD 10.55 billion by 2034, the forecast period compounding at 5.88% a year.
- 42% of 2025 revenue sits in Indwelling (Foley) Catheters (USD 2.646 billion) and it remains the largest product line in 2034 at USD 3.798 billion and 36%.
- At 8.08%, Intermittent Catheters grows faster than any other product line, moving from USD 2.142 billion and 34% of revenue in 2025 to USD 4.326 billion and 41% in 2034.
- The bull case puts 2034 revenue at USD 11.605 billion and the bear case at USD 9.284 billion, either side of the USD 10.55 billion base case, each with its own stated assumption in the full report.
- 37% of 2025 revenue is generated in North America, worth USD 2.331 billion and rising to USD 3.587 billion by 2034; Middle East and Africa is smallest at 6%.
- The United States accounts for 88% of North America in the base year, worth USD 2.051 billion in 2025 and reaching USD 3.157 billion by 2034, the worked country example carried through that region's chapters.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and seven segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By Product
Base year 2025Indwelling (Foley) Catheters leads with 42.0% of product segment revenue.
Share of product segment revenue, most recent base year.
Three things move over 2026-2034, and they are worth separating: the product mix, the regional balance, and the 5.88% compounding underneath both.
None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.
The product mix tilts toward Intermittent Catheters. Between 2026 and 2034, 8.08% growth in Intermittent Catheters against 4.07% in Indwelling (Foley) Catheters pulls the product mix apart. Intermittent Catheters takes its share of revenue from 34% to 41% while Indwelling (Foley) Catheters gives up ground, from 42% to 36%. The revenue figures behind that are USD 2.142 billion to USD 4.326 billion and USD 2.646 billion to USD 3.798 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.
Asia Pacific gain regional share. Asia Pacific moves from 24% of revenue in 2025 to 29% in 2034, worth USD 1.512 billion rising to USD 3.06 billion. The offsetting side is North America at 37% moving to 34%, Europe at 26% moving to 24%, Latin America at 7% moving to 7%, Middle East and Africa at 6% moving to 6%, none of which contracts. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
Growth compounds at 5.88% without a step change. The market moves through USD 4.55 billion in 2020, USD 6.05 billion in 2024, USD 6.3 billion in 2025, USD 6.68 billion in 2026, USD 8.45 billion in 2030 and USD 10.55 billion in 2034. Against 6.72% through the historical period, the 5.88% forecast rate is a continuation; no year in the series interrupts it. For a participant that makes planning a question of capturing a share of steady expansion rather than timing a discontinuity, and it is why the product and regional mixes matter more to a forecast than the headline rate does.
Market Growth Factors
Intermittent Catheters adds the most incremental growth
Market Drivers
3- 01Intermittent Catheters adds the most incremental growth
The fastest line on the product axis is Intermittent Catheters, at 8.08% against the market's 5.88%, taking USD 2.142 billion to USD 4.326 billion and 34% of revenue to 41%. Nothing else on the axis grows as fast (Indwelling (Foley) Catheters manages 4.07%) so the blended 5.88% is carried by this one line rather than shared across them. That makes position on the product axis a growth decision rather than a product one.
- 02North America carries 37% of the base and keeps growing
37% of 2025 revenue (USD 2.331 billion) is generated in North America, reaching USD 3.587 billion by 2034 at an unchanged 34%. Europe adds a further 26% at USD 1.638 billion, reaching USD 2.532 billion. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03The trend is already in the record
USD 4.55 billion in 2020, USD 6.05 billion in 2024 and USD 6.3 billion in 2025: 6.72% compound growth before the forecast period even begins. The forecast period then runs at 5.88%, ending 2034 at USD 10.55 billion. With the trajectory already demonstrated over fifteen years, what remains uncertain is the mix rather than the direction, which is where the segment and regional sections do the work.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising prevalence of urinary incontinence and chronic urological conditions among aging populations | High | +1.65 | High | High | High |
| 2 | Shift toward home-based intermittent self-catheterization to reduce hospital-acquired infection risk | High | +1.35 | Medium | High | High |
| 3 | Increasing adoption of hydrophilic-coated catheters to lower infection and urethral trauma rates | Medium-High | +0.85 | High | Medium | Medium |
| 4 | Growing volume of surgical procedures requiring post-operative catheterization | Medium | +0.55 | Medium | Medium | Medium |
| 5 | Expanding public and private insurance reimbursement for catheter supplies in developed markets | Medium | +0.4 | Low | Medium | Medium |
| 6 | Others | Low | +0.2 | Low | Low | Low |
| Total | +5 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Procurement budget constraints and tender pricing pressure in cost-sensitive health systems | Medium | −0.45 | High | Medium | Medium |
| 2 | Infection-control protocols favoring shorter catheter dwell times over continued use | Medium | −0.2 | Medium | Medium | Low |
| 3 | Reimbursement gaps limiting home-care catheter adoption in lower-income regions | Low | −0.1 | Low | Low | Low |
| Total | −0.75 | |||||
Drivers contribute 5 Billion and restraints remove 0.75 Billion, a net 4.25 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Growth in the global urinary catheters market comes from three measurable sources over 2026-2034: the market's own compounding at 5.88%, the share gained by faster-growing product lines, and expansion in the regions taking a larger part of global revenue.
Restraining Factors
Downside case: USD 9.284 billion rather than USD 10.55 billion by 2034
Market Restraints
2- 01Downside case: USD 9.284 billion rather than USD 10.55 billion by 2034
The study's downside path assumes the bear case assumes tighter hospital procurement budgets and slower rollout of home-care catheterization programs across Europe and North America hold volume growth below the base case through the forecast period, and ends 2034 at USD 9.284 billion against the USD 10.55 billion base case, the same USD 6.3 billion base year, a slower forecast period.
- 02Indwelling (Foley) Catheters grows below the market rate
Indwelling (Foley) Catheters carries 42% of 2025 revenue at USD 2.646 billion but compounds at 4.07% against 5.88% for the market, taking its share to 36% by 2034 even as revenue rises to USD 3.798 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
A bull case of USD 11.605 billion by 2034, against USD 10.55 billion in the base case, turns on a single stated assumption: the bull case assumes faster public and private reimbursement approval for intermittent self-catheterization products across Asia Pacific and Latin America, pulling adoption that would otherwise phase in later in the forecast period into earlier years. The USD 6.3 billion 2025 base is common to both.
- 02The opening is on the product axis, not the regional one
Share on the product axis moves toward Intermittent Catheters, from 34% in 2025 to 41% in 2034, on 8.08% growth against the market's 5.88% and revenue rising from USD 2.142 billion to USD 4.326 billion. Taking position there does not require displacing whoever holds Indwelling (Foley) Catheters, which is the harder and more expensive fight.
Market Challenges
Concentration on the product axis
Market Challenges
2- 01Concentration on the product axis
With 42% of 2025 revenue and 36% of 2034 revenue (USD 2.646 billion rising to USD 3.798 billion) Indwelling (Foley) Catheters is where the market's exposure sits. Anything that changes demand for it changes the headline number; nothing else on the axis carries that weight.
- 02The United States is 88% of North America
88% of the leading region is one country: the United States, at USD 2.051 billion against North America's USD 2.331 billion in 2025, and USD 3.157 billion by 2034. A regional number that depends this heavily on one country carries that country's specific conditions inside it, which a reader treating the region as diversified would miss.
Segmentation Analysis
7 axesThe global urinary catheters market is cut seven ways: by product, coating type, material, application, gender, end use and distribution channel. They are alternative readings of one revenue pool, not parts that sum to it.
There are four lines on the product axis, and all of them grow in revenue between 2025 and 2034. What separates them is share: one gains it, the rest give it up.
By Product · 4 segments
Indwelling (Foley) Catheters Held the Dominant Share of the Product Segment in 2025
- Largest Indwelling (Foley) Catheters · 42%
- Fastest Intermittent Catheters · 8.1%
- Moves most Intermittent Catheters · +7 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Indwelling (Foley) Catheters | $2.65B | 42% | $3.80B | 36%-6 | 4.1% |
| Intermittent Catheters | $2.14B | 34% | $4.33B | 41%+7 | 8.1% |
| External Catheters | $1.01B | 16% | $1.58B | 15%-1 | 5.1% |
| Suprapubic Catheter | $0.50B | 8% | $0.84B | 8% | 5.9% |
Indwelling Foley catheters retain the largest share because hospitals still rely on them for continuous urine drainage during acute inpatient stays and post-surgical recovery, where an established, low-cost device remains the default choice. Intermittent catheters grow fastest as clinicians and payers favor periodic self-catheterization to lower infection risk and support patients managing bladder dysfunction at home. By 2034 the largest line is Intermittent Catheters rather than Indwelling (Foley) Catheters, the one axis here where the order actually changes. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Coating Type · 2 segments
Coated Catheters Both Leads the Coating type Axis and Grows Fastest on It
- Largest Coated Catheters · 58%
- Fastest Coated Catheters · 7.3%
- Moves most Coated Catheters · +7 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Coated Catheters | $3.65B | 58% | $6.86B | 65%+7 | 7.3% |
| Uncoated Catheters | $2.65B | 42% | $3.69B | 35%-7 | 3.8% |
Coated catheters lead because hydrophilic and antimicrobial coatings reduce urethral friction and lower the risk of catheter-associated urinary tract infection, a clinical priority in both hospital and home-care settings. Coated products also grow faster as reimbursement policies and infection-control guidelines increasingly favor them over plain, uncoated devices for repeat or long-term use. The order does not change: Coated Catheters is still largest in 2034, and what moves is how much it holds.
By Material · 5 segments
Silicone Both Leads the Material Axis and Grows Fastest on It
- Largest Silicone · 38%
- Fastest Silicone · 7.4%
- Moves most Silicone · +5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Silicone | $2.39B | 38% | $4.54B | 43%+5 | 7.4% |
| Latex | $1.13B | 18% | $1.37B | 13%-5 | 2.1% |
| Silicone-Coated Latex | $1.39B | 22% | $2.32B | 22% | 5.9% |
| PVC | $0.88B | 14% | $1.48B | 14% | 5.9% |
| Other Materials | $0.50B | 8% | $0.84B | 8% | 5.9% |
Silicone remains the leading material because it is biocompatible, flexible over long dwell periods, and free of the allergy concerns associated with natural rubber latex, making it the preferred choice for both indwelling and intermittent devices. Silicone also grows fastest as manufacturers and hospitals continue shifting away from latex-based products toward hypoallergenic alternatives. The order does not change: Silicone is still largest in 2034, and what moves is how much it holds.
By Application · 8 segments
By Application
- Largest Urinary Incontinence · 27%
- Fastest Chronic Urinary Retention · 7.1%
- Moves most Benign Prostate Hyperplasia (BPH) · -2 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Urinary Incontinence | $1.70B | 27% | $2.95B | 28%+1 | 6.3% |
| Benign Prostate Hyperplasia (BPH) | $1.13B | 18% | $1.69B | 16%-2 | 4.5% |
| Spinal Cord Injury | $0.63B | 10% | $0.95B | 9%-1 | 4.7% |
| Post-Surgical Urinary Retention | $0.88B | 14% | $1.48B | 14% | 5.9% |
| Neurogenic Bladder | $0.76B | 12% | $1.37B | 13%+1 | 6.8% |
| Chronic Urinary Retention | $0.57B | 9% | $1.05B | 10%+1 | 7.1% |
| Prostate Cancer | $0.38B | 6% | $0.63B | 6% | 5.9% |
| Other Urological Conditions | $0.25B | 4% | $0.42B | 4% | 5.9% |
2025 to 2034 revenue and share by line: Urinary Incontinence USD 1.701 billion to USD 2.954 billion (27% to 28%), Benign Prostate Hyperplasia (BPH) USD 1.134 billion to USD 1.688 billion (18% to 16%), Post-Surgical Urinary Retention USD 0.882 billion to USD 1.477 billion (14% to 14%), Neurogenic Bladder USD 0.756 billion to USD 1.372 billion (12% to 13%), Spinal Cord Injury USD 0.63 billion to USD 0.95 billion (10% to 9%), Chronic Urinary Retention USD 0.567 billion to USD 1.055 billion (9% to 10%), Prostate Cancer USD 0.378 billion to USD 0.633 billion (6% to 6%), Other Urological Conditions USD 0.252 billion to USD 0.422 billion (4% to 4%). Urinary Incontinence Led by Application in 2025, with Chronic Urinary Retention Growing Fastest Urinary incontinence leads because it affects the largest and most diverse patient population, spanning age-related, post-surgical and neurological causes that all require some form of catheter management. Chronic urinary retention and neurogenic bladder grow fastest as earlier diagnosis and longer patient survival with spinal and neurological conditions expand the pool of patients needing ongoing catheter-based bladder management. By 2034 Urinary Incontinence is still ahead, making this a shift in weight rather than a change of leader.
By Gender · 2 segments
Male Led by Gender in 2025, with Female Growing Fastest
- Largest Male · 58%
- Fastest Female · 6.2%
- Moves most Male · -1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Male | $3.65B | 58% | $6.01B | 57%-1 | 5.7% |
| Female | $2.65B | 42% | $4.54B | 43%+1 | 6.2% |
Male patients account for the larger share because prostate enlargement and related urinary retention drive a substantial portion of catheter use in men, in addition to incontinence and post-surgical needs shared with women. Demand among female patients grows faster as awareness and treatment of female incontinence and neurogenic bladder conditions continue to expand. Female grows fastest here, so its share rises while Male gives ground. Male remains the largest line through 2034, so the axis changes in proportion rather than in order.
By End Use · 5 segments
Hospitals Led by End use in 2025, with Home Care Settings Growing Fastest
- Largest Hospitals · 44%
- Fastest Home Care Settings · 8.8%
- Moves most Home Care Settings · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals | $2.77B | 44% | $4.12B | 39%-5 | 4.5% |
| Ambulatory Surgical Centers (ASCs) | $0.44B | 7% | $0.74B | 7% | 5.9% |
| Clinics | $0.69B | 11% | $1.05B | 10%-1 | 4.8% |
| Long-term Care Facilities/Nursing Homes | $1.01B | 16% | $1.69B | 16% | 5.9% |
| Home Care Settings | $1.39B | 22% | $2.95B | 28%+6 | 8.8% |
Hospitals lead because acute inpatient care, surgical recovery and emergency catheterization all concentrate around hospital settings with trained clinical staff. Home care settings grow fastest as intermittent self-catheterization shifts routine, long-term catheter use out of institutional settings and toward patients managing their own bladder health at home, supported by simpler, easier-to-use devices. Hospitals remains the largest line through 2034, so the axis changes in proportion rather than in order.
By Distribution Channel · 4 segments
Direct Tenders Led by Distribution channel in 2025, with Online Channels Growing Fastest
- Largest Direct Tenders · 40%
- Fastest Online Channels · 13.1%
- Moves most Online Channels · +8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Direct Tenders | $2.52B | 40% | $3.69B | 35%-5 | 4.3% |
| Distributors/Wholesalers | $1.89B | 30% | $2.95B | 28%-2 | 5.1% |
| Retail Pharmacies | $1.26B | 20% | $2B | 19%-1 | 5.3% |
| Online Channels | $0.63B | 10% | $1.90B | 18%+8 | 13.1% |
Direct tenders lead because hospitals and large healthcare systems procure catheters in bulk through negotiated contracts with manufacturers, which keeps per-unit costs predictable for high-volume institutional buyers. Online channels grow fastest as home-care patients increasingly reorder intermittent catheter supplies directly through e-commerce and subscription-style delivery services rather than through a physical pharmacy visit. Direct Tenders remains the largest line through 2034, so the axis changes in proportion rather than in order.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 3 points of share move elsewhere by 2034.
- Rank 1 of 5
- 2025 share 37%
- By 2034 34%
- Revenue $2.33B → $3.59B
North America holds 37% of the global urinary catheters market in 2025, worth USD 2.331 billion rising to USD 3.587 billion in 2034. That makes it the first-largest region covered, in 2025 and again in 2034.
34% of global revenue sits here in 2034, below the 2025 level, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Indwelling (Foley) Catheters leads here as it does globally, at 42% of 2025 revenue, and Intermittent Catheters again grows fastest at 8.08%. Per-axis and per-country detail for North America sits in the full report.
United States
Sets the pace for North America at 88% of it, growing 1.5×.
- In region 1 of 2
- Of region 88%
- Of global 32.6%
- Revenue $2.05B → $3.16B
The largest single market in North America is the United States, at USD 2.051 billion in 2025 and USD 3.157 billion in 2034. 88% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Regional revenue of USD 2.331 billion in 2025 and USD 3.587 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in the United States follows the product mix reported at global level: Indwelling (Foley) Catheters is the largest line at 42% of 2025 revenue, moving to 36% by 2034, while Intermittent Catheters grows fastest at 8.08% and takes its share from 34% to 41%. Since 88% of North America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-product revenue for the United States appears on its own in the full report.
In the United States, urinary catheters are regulated by the Food and Drug Administration as medical devices, subject to classification under the Federal Food, Drug, and Cosmetic Act's device framework. Most catheter types fall under premarket notification requirements, meaning a manufacturer must demonstrate substantial equivalence to a legally marketed predicate device before the FDA authorizes commercial distribution. Establishments must also register facilities and list products with the agency, comply with the Quality System Regulation governing manufacturing controls, and meet labelling requirements that clearly state intended use, sterility status, and handling instructions. Ongoing conformity with recognized consensus standards for biocompatibility and sterility is expected throughout the product's marketed life.
Coloplast Corp, B. Braun SE, Medline Industries, LP., Hollister Incorporated, Cook, Teleflex Incorporated, BD (Bard Medical), ConvaTec Group Plc, Wellspect HealthCare, Cardinal Health, Bactiguard AB, Amsino International and Flexicare Medical Limited are the suppliers covered in the United States. Indwelling (Foley) Catheters, at 42% of 2025 revenue, is where the volume sits, and Intermittent Catheters, growing at 8.08%, is where position changes hands over the forecast period. Country-level positioning and shares for each of these companies are part of the full report rather than this summary.
Canada
2nd-largest in North America, growing 1.5×.
- In region 2 of 2
- Of region 12%
- Of global 4.4%
- Revenue $0.28B → $0.43B
Within North America, Canada accounts for 12% of regional revenue and 4.44% of the global total, worth USD 0.28 billion in 2025 and USD 0.43 billion by 2034.
Europe Market Analysis
The 2nd-largest region covered — 2 points of share move elsewhere by 2034.
- Rank 2 of 5
- 2025 share 26%
- By 2034 24%
- Revenue $1.64B → $2.53B
USD 1.638 billion of 2025 revenue is generated in Europe, 26% of the global urinary catheters market rising to USD 2.532 billion in 2034. Among the five regions it ranks second by revenue in both years.
Share settles at 24% in 2034, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Segment composition follows the global pattern: Indwelling (Foley) Catheters largest at 42% of 2025 revenue, Intermittent Catheters fastest at 8.08%. The full report breaks Europe out along every axis and by country.
Germany
The largest market in Europe, growing 1.5×.
- In region 1 of 3
- Of region 30%
- Of global 7.8%
- Revenue $0.49B → $0.76B
The largest single market in Europe is Germany, at USD 0.491 billion in 2025 and USD 0.76 billion in 2034. Its 30% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Against regional totals of USD 1.638 billion in 2025 and USD 2.532 billion in 2034, it is the country the full report breaks out in detail.
Demand in Germany follows the product mix reported at global level: Indwelling (Foley) Catheters is the largest line at 42% of 2025 revenue, moving to 36% by 2034, while Intermittent Catheters grows fastest at 8.08% and takes its share from 34% to 41%. Because the country carries 30% of Europe, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Germany carries its own product breakdown in the full report.
In Germany, urinary catheters fall under the European Union's Medical Device Regulation, enforced domestically through the Medical Device Act and overseen by the national competent authority, BfArM, alongside notified bodies that conduct conformity assessments. Depending on their risk classification, manufacturers typically need notified-body involvement before affixing the CE mark, which is mandatory for placing the product on the German and wider European market. Suppliers must maintain technical documentation, a quality management system, and post-market surveillance processes, while labelling must meet the Regulation's requirements on traceability, intended purpose, and language-appropriate instructions for use. Compliance with harmonized standards for sterile single-use devices is also expected.
Competition in Germany runs between the suppliers this study tracks: Coloplast Corp, B. Braun SE, Medline Industries, LP., Hollister Incorporated, Cook, Teleflex Incorporated, BD (Bard Medical), ConvaTec Group Plc, Wellspect HealthCare, Cardinal Health, Bactiguard AB, Amsino International and Flexicare Medical Limited. The commercially relevant division is 42% of 2025 revenue in Indwelling (Foley) Catheters, where the volume is, against 8.08% growth in Intermittent Catheters, where share moves.
United Kingdom
2nd-largest in Europe, growing 1.5×.
- In region 2 of 3
- Of region 25%
- Of global 6.5%
- Revenue $0.41B → $0.63B
The United Kingdom is sized at USD 0.41 billion in 2025, rising to USD 0.633 billion by 2034; 6.5% of global revenue and 25% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 1.5×.
- In region 3 of 3
- Of region 20%
- Of global 5.2%
- Revenue $0.33B → $0.51B
France is sized at USD 0.328 billion in 2025, rising to USD 0.506 billion by 2034; 5.2% of global revenue and 20% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 5 points of share by 2034, while revenue still grows 2.0×.
- Rank 3 of 5
- 2025 share 24%
- By 2034 29%
- Revenue $1.51B → $3.06B
Asia Pacific holds 24% of the global urinary catheters market in 2025, worth USD 1.512 billion on the way to USD 3.06 billion by 2034. Among the five regions it ranks third by revenue in both years.
29% of global revenue sits here by 2034, up from the 2025 level, so the region grows faster than the market's 5.88% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
The product mix reported at global level applies here, with Indwelling (Foley) Catheters the largest line at 42% of 2025 revenue and Intermittent Catheters the fastest-growing at 8.08%. Per-axis and per-country detail for Asia Pacific sits in the full report.
China
The largest market in Asia Pacific, growing 2.0×.
- In region 1 of 3
- Of region 35%
- Of global 8.4%
- Revenue $0.53B → $1.07B
China is the largest market within Asia Pacific, generating USD 0.529 billion in 2025 and projected to reach USD 1.071 billion by 2034. Its 35% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 1.512 billion in 2025 and USD 3.06 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
China buys along the same lines as the market globally; Indwelling (Foley) Catheters first at 42% of 2025 revenue and 36% in 2034, Intermittent Catheters fastest at 8.08% on a share moving from 34% to 41%. Because the country carries 35% of Asia Pacific, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Per-product revenue for China appears on its own in the full report.
In China, urinary catheters are regulated by the National Medical Products Administration, which classifies medical devices by risk and requires registration before a product may be legally sold. Depending on classification, a supplier must submit clinical evaluation data, product testing reports, and quality system evidence to a provincial or national review body, and manufacturing facilities are subject to inspection under the country's Good Manufacturing Practice requirements for medical devices. Imported catheters generally require a local agent and Chinese-language labelling that discloses intended use, sterility, and handling precautions. Registration certificates must be renewed periodically, and any change to the device's design or manufacturing process typically triggers a fresh regulatory review.
Competition in China runs between the suppliers this study tracks: Coloplast Corp, B. Braun SE, Medline Industries, LP., Hollister Incorporated, Cook, Teleflex Incorporated, BD (Bard Medical), ConvaTec Group Plc, Wellspect HealthCare, Cardinal Health, Bactiguard AB, Amsino International and Flexicare Medical Limited. Volume sits in Indwelling (Foley) Catheters at 42% of 2025 revenue; movement sits in Intermittent Catheters at 8.08% growth.
Japan
2nd-largest in Asia Pacific, growing 2.0×.
- In region 2 of 3
- Of region 22%
- Of global 5.3%
- Revenue $0.33B → $0.67B
Within Asia Pacific, Japan accounts for 22% of regional revenue and 5.28% of the global total, worth USD 0.333 billion in 2025 and USD 0.673 billion by 2034.
India
3rd-largest in Asia Pacific, growing 2.0×.
- In region 3 of 3
- Of region 15%
- Of global 3.6%
- Revenue $0.23B → $0.46B
3.6% of global revenue is generated in India; USD 0.227 billion in 2025, reaching USD 0.459 billion in 2034, and 15% of Asia Pacific.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 1.7×.
- Rank 4 of 5
- 2025 share 7%
- By 2034 7%
- Revenue $0.44B → $0.74B
7% of the global urinary catheters market sits in Latin America in 2025, worth USD 0.441 billion rising to USD 0.739 billion in 2034. Among the five regions it ranks fourth by revenue in both years.
7% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Segment composition follows the global pattern: Indwelling (Foley) Catheters largest at 42% of 2025 revenue, Intermittent Catheters fastest at 8.08%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.
Brazil
The largest market in Latin America, growing 1.7×.
- In region 1 of 2
- Of region 45%
- Of global 3.1%
- Revenue $0.20B → $0.33B
The largest single market in Latin America is Brazil, at USD 0.198 billion in 2025 and USD 0.332 billion in 2034. It accounts for 45% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 0.441 billion in 2025 and USD 0.739 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
The product pattern in Brazil is the global one: 42% of 2025 revenue in Indwelling (Foley) Catheters, 36% by 2034, against 8.08% growth in Intermittent Catheters taking it from 34% to 41%. Its 45% weight in Latin America means those movements carry straight into the regional totals. Brazil carries its own product breakdown in the full report.
In Brazil, urinary catheters are regulated by ANVISA, the national health surveillance agency, which requires medical devices to be registered or notified depending on their risk classification before commercial distribution is permitted. Higher-risk catheter types generally require full registration with supporting evidence of safety and performance, while lower-risk variants may proceed through a simplified notification route. Manufacturers and importers must hold a valid operating authorization, comply with Brazil's Good Manufacturing Practice certification requirements, and ensure labelling is presented in Portuguese with clear statements of intended use, sterility, and expiry. ANVISA also expects adherence to recognized quality and safety standards for single-use sterile devices throughout the product lifecycle.
Coloplast Corp, B. Braun SE, Medline Industries, LP., Hollister Incorporated, Cook, Teleflex Incorporated, BD (Bard Medical), ConvaTec Group Plc, Wellspect HealthCare, Cardinal Health, Bactiguard AB, Amsino International and Flexicare Medical Limited are the suppliers covered in Brazil. Volume sits in Indwelling (Foley) Catheters at 42% of 2025 revenue; movement sits in Intermittent Catheters at 8.08% growth.
Mexico
2nd-largest in Latin America, growing 1.7×.
- In region 2 of 2
- Of region 30%
- Of global 2.1%
- Revenue $0.13B → $0.22B
Within Latin America, Mexico accounts for 30% of regional revenue and 2.1% of the global total, worth USD 0.132 billion in 2025 and USD 0.222 billion by 2034.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 1.7×.
- Rank 5 of 5
- 2025 share 6%
- By 2034 6%
- Revenue $0.38B → $0.63B
In Middle East and Africa, 6% of global revenue puts 2025 at USD 0.378 billion and reaches USD 0.633 billion by 2034. Among the five regions it ranks fifth by revenue in both years.
Share settles at 6% in 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.
Segment composition follows the global pattern: Indwelling (Foley) Catheters largest at 42% of 2025 revenue, Intermittent Catheters fastest at 8.08%. Middle East and Africa is reported axis by axis and country by country in the full study.
Saudi Arabia
The largest market in Middle East and Africa, growing 1.7×.
- In region 1 of 2
- Of region 28%
- Of global 1.7%
- Revenue $0.11B → $0.18B
USD 0.106 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.177 billion by 2034. 28% of the region in the base year makes it the largest market here without making it the region. Set against USD 0.378 billion and USD 0.633 billion for the region, it is why this market rather than a smaller one is the one reported in full.
Composition here matches the global split: the largest line is Indwelling (Foley) Catheters at 42% of 2025 revenue, easing to 36% by 2034, and the fastest is Intermittent Catheters at 8.08%, from 34% to 41%. Because the country carries 28% of Middle East and Africa, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Saudi Arabia by product separately.
In Saudi Arabia, urinary catheters are regulated by the Saudi Food and Drug Authority, which oversees medical device registration through its national Medical Devices Interim Regulation framework. Suppliers must classify the device according to risk, register the product and the establishment through the authority's electronic system, and demonstrate conformity with recognized international standards for safety and performance, often relying on prior approval from a reference regulatory body as supporting evidence. Labelling must appear in Arabic, stating intended use, sterility status, and handling precautions, and an authorized local representative is generally required for manufacturers based outside the Kingdom. Post-market vigilance reporting obligations also apply once the device is in distribution.
Coloplast Corp, B. Braun SE, Medline Industries, LP., Hollister Incorporated, Cook, Teleflex Incorporated, BD (Bard Medical), ConvaTec Group Plc, Wellspect HealthCare, Cardinal Health, Bactiguard AB, Amsino International and Flexicare Medical Limited are the suppliers covered in Saudi Arabia. Two different problems sit on the same axis: holding Indwelling (Foley) Catheters at 42% of 2025 revenue, and taking Intermittent Catheters while it grows at 8.08%.
South Africa
2nd-largest in Middle East and Africa, growing 1.7×.
- In region 2 of 2
- Of region 20%
- Of global 1.2%
- Revenue $0.08B → $0.13B
Within Middle East and Africa, South Africa accounts for 20% of regional revenue and 1.2% of the global total, worth USD 0.076 billion in 2025 and USD 0.127 billion by 2034.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product, Coating Type, Material, Application, Gender, End Use, Distribution Channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in Indwelling (Foley) Catheters and Growth in Intermittent Catheters Set the Terms of Competition
The study covers the following suppliers: Coloplast Corp, B. Braun SE, Medline Industries, LP., Hollister Incorporated, Cook, Teleflex Incorporated, BD (Bard Medical), ConvaTec Group Plc, Wellspect HealthCare, Cardinal Health, Bactiguard AB, Amsino International and Flexicare Medical Limited.
Competition follows the product split rather than the regional one. Volume sits in Indwelling (Foley) Catheters, USD 2.646 billion and 42% of 2025 revenue, 36% by 2034, which is also where an incumbent is hardest to dislodge. Movement is concentrated in Intermittent Catheters; 8.08% growth, against 4.07% at the other end of the axis in Indwelling (Foley) Catheters. Holding the first and taking the second are separate capabilities, which is why a market of USD 6.3 billion supports as many suppliers as it does.
In this market, the largest suppliers compete on manufacturing scale and consistent supply across coating, material and size variants, paired with a long regulatory track record that gives hospital purchasing committees confidence in a device inserted directly into a sensitive anatomical site. Distribution reach into hospital tenders, group-purchasing contracts and home-care delivery networks further separates established players from newer entrants. Smaller and regional manufacturers instead compete on price within retail pharmacy and distributor channels, on local tender relationships, and on serving specific national reimbursement systems that larger multinational suppliers are slower to adapt product lines for.
Geographic reach is the other axis of competition. North America alone accounts for 37% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 26%.
Profiles, financials, shares and development histories for each company sit in the full report; this summary carries the structure only.
List of Key Urinary Catheters Market Companies Profiled
13 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Coloplast Corp(Denmark)
- B. Braun SE(Germany)
- Medline Industries, LP.(United States)
- Hollister Incorporated(United States)
- Cook(United States)
- Teleflex Incorporated(United States)
- BD (Bard Medical)(United States)
- ConvaTec Group Plc(United Kingdom)
- Wellspect HealthCare(Sweden)
- Cardinal Health(United States)
- Bactiguard AB(Sweden)
- Amsino International(United States)
- Flexicare Medical Limited(United Kingdom)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Industry Developments
1 reported events- November 2025Hollister Incorporated Drives Major Policy Change to Expand Access to Closed System Intermittent Catheters for People with Spinal Cord InjuriesHollister Incorporated · PR Newswire
Developments reported by the publishers named, summarised where noted; each links through Google News to the published article.
Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 7 axes (Product, Coating Type, Material, Application, Gender, End Use, Distribution Channel), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 13 key companies, and the research methodology behind every estimate.
Segmentation
7 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Urinary Catheters Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Urinary Catheters Market Overview, By Product, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Urinary Catheters Market Overview, By Coating Type, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Urinary Catheters Market Overview, By Material, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Urinary Catheters Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Urinary Catheters Market Overview, By Gender, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Urinary Catheters Market Overview, By End Use, 2020–2034, Revenue (USD Billion)
Chapter 22.Global Urinary Catheters Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Chapter 23.Global Urinary Catheters Market Size — Segment Comparison
Chapter 24.Global Urinary Catheters Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 25.North America Urinary Catheters Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Europe Urinary Catheters Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Asia Pacific Urinary Catheters Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Latin America Urinary Catheters Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 29.Middle East and Africa Urinary Catheters Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 30.Application / Use-Case Analysis
Chapter 31.Vendor Capability Scorecard
Chapter 32.Scenario Forecasts
Chapter 33.Top 10 Key Clients of Top 10 Players
Chapter 34.Top 10 Suppliers
Chapter 35.Competitive Landscape
Chapter 36.Partnerships & M&A
Chapter 37.Key Vendor Analysis
Chapter 38.Marketing Strategy Analysis, Distributors & Traders
Chapter 39.Outlook of the Market
Chapter 40.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
7 axesBy Product
4- 01Indwelling (Foley) Catheters
- 02Intermittent Catheters
- 03External Catheters
- 04Suprapubic Catheter
By Coating Type
2- 01Coated Catheters
- 02Uncoated Catheters
By Material
5- 01Silicone
- 02Latex
- 03Silicone-Coated Latex
- 04PVC
- 05Other Materials
By Application
8- 01Urinary Incontinence
- 02Benign Prostate Hyperplasia (BPH)
- 03Spinal Cord Injury
- 04Post-Surgical Urinary Retention
- 05Neurogenic Bladder
- 06Chronic Urinary Retention
- 07Prostate Cancer
- 08Other Urological Conditions
By Gender
2- 01Male
- 02Female
By End Use
5- 01Hospitals
- 02Ambulatory Surgical Centers (ASCs)
- 03Clinics
- 04Long-term Care Facilities/Nursing Homes
- 05Home Care Settings
By Distribution Channel
4- 01Direct Tenders
- 02Distributors/Wholesalers
- 03Retail Pharmacies
- 04Online Channels
Segment categories shown for scope reference. See the Summary tab for revenue share by Product. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
Sizing for this market combines a bottom-up build from catheterization volumes with a top-down check against institutional and patient spending. The bottom-up track estimates the number of catheterization episodes and device units across hospitals, long-term care facilities and home-care patients, informed by procedure and discharge volumes, average dwell-time and device-replacement frequency by product type, then applies unit pricing that varies by material, coating and channel. The top-down track cross-checks this against hospital procurement budgets, tender values and out-of-pocket and reimbursed patient spending on continence and urology supplies. Where the two tracks diverge, the estimate is weighted toward the bottom-up volume build, since device-level replacement patterns are better documented than aggregate procurement spending across fragmented regional tender data.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research for this market prioritizes interviews with hospital procurement and materials-management staff, urology and continence-care clinicians, distributor and group-purchasing-organization contacts, and regulatory-affairs personnel at device manufacturers who can speak to product approval timelines across major markets. Sampling emphasizes the United States, Germany, the United Kingdom, China and Japan, the geographies that carry the largest share of institutional procurement and device registration activity, supplemented by conversations with home-care distributors in markets where intermittent self-catheterization is gaining share. These conversations validate device-mix assumptions, coating and material adoption trends, channel economics and regional pricing differences that the desk-research build cannot capture on its own.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Urinary Catheters Market projected to reach?
USD 10.55 Billion by 2034, CAGR 5.88%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 37% of global revenue through 2034.
05Which segment leads the market?
Indwelling (Foley) Catheters is the largest line by Product, at 42% of revenue in 2025.
06Who are the key companies profiled?
Coloplast Corp, B. Braun SE, Medline Industries, LP., Hollister Incorporated, Cook, Teleflex Incorporated, BD (Bard Medical), ConvaTec Group Plc, Wellspect HealthCare, Cardinal Health, Bactiguard AB, Amsino International, Flexicare Medical Limited. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.